GSK plc Buys Back Own Shares
Ticker: GLAXF · Form: 6-K · Filed: Oct 8, 2025 · CIK: 1131399
| Field | Detail |
|---|---|
| Company | Gsk PLC (GLAXF) |
| Form Type | 6-K |
| Filed Date | Oct 8, 2025 |
| Risk Level | low |
| Pages | 10 |
| Reading Time | 12 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: share-buyback, transaction
TL;DR
GSK is buying back its own stock via BNP Paribas.
AI Summary
GSK plc announced on October 8, 2025, that it purchased a certain number of its own ordinary shares, each with a nominal value of 31 1/4 pence. The transactions were executed through its broker, BNP Paribas SA.
Why It Matters
Share buybacks can signal management's confidence in the company's valuation and potentially increase earnings per share.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of share repurchases and does not indicate any new or significant risks.
Key Players & Entities
- GSK plc (company) — The company making the share repurchase.
- BNP Paribas SA (company) — The broker executing the share repurchase on behalf of GSK plc.
- 31 1/4 pence (dollar_amount) — The nominal value of each ordinary share purchased by GSK plc.
FAQ
What is the purpose of this Form 6-K filing?
This Form 6-K filing reports on GSK plc's transactions in its own shares during the month of October 2025.
Who is acting as the broker for GSK plc's share repurchases?
BNP Paribas SA is acting as the broker for GSK plc's share repurchases.
What is the nominal value of GSK plc's ordinary shares?
The nominal value of GSK plc's ordinary shares is 31 1/4 pence each.
When did GSK plc announce these share repurchases?
GSK plc announced these share repurchases on October 8, 2025.
Does GSK plc file annual reports under Form 20-F or Form 40-F?
GSK plc indicates that it files annual reports under cover of Form 20-F.
Filing Stats: 3,067 words · 12 min read · ~10 pages · Grade level 2.8 · Accepted 2025-10-08 06:27:45
Filing Documents
- a4535c.htm (6-K) — 3523KB
- 0001654954-25-011559.txt ( ) — 3524KB
From the Filing
IN OWN SHARES a4535c   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Form 6-K   REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934       For the month of October 2025   Commission File Number 001-15170     GSK plc (Translation of registrant's name into English)     79 New Oxford Street, London, WC1A 1DG (Address of principal executive office)       Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.   Form 20-F . . . .X. . . . Form 40-F . . . . . . . .     Transaction in own shares   GSK plc (the " Company ") announces today   acting through BNP Paribas SA (the " Broker "), it has purchased the following number of the Company's ordinary shares of  31¼  pence each.   Date of purchase: 07 October 2025   Aggregate number of ordinary shares of  31¼  pence each purchased: 354,000   Lowest price paid per share (GBp): 1,597.50p   Highest price paid per share (GBp): 1,611.50p   Volume-weighted average price paid per share (GBp): 1,603.99p     The purchased shares will be held   as Treasury shares.                                                                                                                            Such purchase forms part of the Company's existing buyback programme and was effected pursuant to the non-discretionary agreement entered into with the Broker, as announced on 30 September 2025. Since 30 September 2025, the Company has purchased 1,946,000 ordinary shares.   Following the above purchase, the Company will hold 249,410,844 ordinary shares in treasury and have 4,065,997,695 ordinary shares in issue (excluding Treasury shares).   The total number of voting rights in the Company is   4,065,997,695. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.   The Company confirms that, in accordance with DTR 5.5.1R, following the above purchase the percentage of voting rights attributable to the ordinary shares held in treasury is 6.13 per cent.   The table below contains detailed information of the individual trades made by the Broker on the London Stock Exchange and the CBOE Europe Limited recognised investment exchange (through its order books having market identification codes CHIX or BATE) as part of the buyback programme.   Schedule of Purchases Shares purchased:   GSK plc (ISIN: GB00BN7SWP63) Date of purchases:   07 October 2025 Investment firm:       BNP Paribas SA     Aggregated information per trading venue:   Venue   Number of ordinary shares purchased   Highest price paid (per ordinary share)(GBp)   Lowest price paid (per ordinary share)(GBp)   Volume weighted average price paid (per ordinary share) (GBp)   BATE   47,970   1,611.50p   1,597.50p   1,603.75p   CHIX   126,786   1,611.50p   1,597.50p   1,603.77p   XLON   179,244   1,611.00p   1,597.50p   1,604.21p     Individual transactions:   Number of Shares   Price per Share (GBp)   Trading venue   Date of transaction   Time of transaction   Transaction reference number   220   1607.0   BATE   07-Oct-2025   08:00:59   20251007146704869   70   1607.0   CHIX   07-Oct-2025   08:00:59   20251007146704871   485   1607.0   XLON   07-Oct-2025   08:00:59   20251007146704873   311   1603.5   XLON   07-Oct-2025   08:01:47   20251007146